3-(4-chlorobenzoyl)-5-methylindolizine-1-carboxylic acid

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-(4-chlorobenzoyl)-5-methylindolizine-1-carboxylic acid
• 英文别名: 3-(4-Chlorobenzoyl)-5-methylindolizine-1-carboxylic acid
• 化学式: C₁₇H₁₂ClNO₃
• 分子量: 313.74
• InChiKey: ANIJCODZGXDFJA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  58.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(4-chlorobenzoyl)-5-methylindolizine-1-carboxylic acid 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 48.0h， 生成 prop-2-yn-1-yl 3-(4-chlorobenzoyl)-5-methylindolizine-1-carboxylate
  参考文献：
  名称：

  Novel indolizine derivatives with unprecedented inhibitory activity on human farnesyltransferase

  摘要：

  The rational structural modification of new substituted indolizin-3-yl(phenyl) methanones 1a-i, 2a-i and 3a-i has greatly improved human farnesyltransferase inhibition. The para-bromophenyl analog 2f bearing an ester unit on the indolizine ring demonstrates the highest inhibition potential, with IC50 value of 1.3 +/- 0.2 mu M. The amidic series 1a-i proves to be the most promising for future modulations, particularly at the triple bond level. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.10.044
• 作为产物：
  描述：

  1-(2-(4-chlorophenyl)-2-oxoethyl)-2-methylpyridinium bromide 在 三乙胺 、 sodium hydroxide 作用下， 以 甲醇 、 二氯甲烷 、 水 为溶剂， 生成 3-(4-chlorobenzoyl)-5-methylindolizine-1-carboxylic acid
  参考文献：
  名称：

  Novel indolizine derivatives with unprecedented inhibitory activity on human farnesyltransferase

  摘要：

  The rational structural modification of new substituted indolizin-3-yl(phenyl) methanones 1a-i, 2a-i and 3a-i has greatly improved human farnesyltransferase inhibition. The para-bromophenyl analog 2f bearing an ester unit on the indolizine ring demonstrates the highest inhibition potential, with IC50 value of 1.3 +/- 0.2 mu M. The amidic series 1a-i proves to be the most promising for future modulations, particularly at the triple bond level. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.10.044